Thymidylate synthase (TYMS) is the main molecular target for fluoropyrimidine anticancer drugs, and its expression has been correlated with the number of repeats of a 28-bp sequence in the 5 0 -untranslated region of the TYMS gene and with the presence of a G-C single-nucleotide polymorphism in the second repeat of 3R alleles. Based on this double polymorphism, three main TYMS alleles have so far been identified: TYMS 2R, TYMS 3RC and TYMS 3RG. During genetic analysis of TYMS polymorphisms in 100 colorectal cancer patients, three patients revealed an unexpected 113-bp band after electrophoresis of the restriction fragment length polymorphism analysis. Subsequent sequencing revealed two 28-bp repeats in the 5 0 -untranslated region and the presence in both repeats of cytosine instead of guanine at the 12th nucleotide. This allele variant (TYMS 2RC) has not been previously described in man. All three patients were heterozygotes for TYMS 2RC and experienced grade 2-3 chemotherapy-related toxicity.
Introduction
Thymidylate synthase (TYMS) catalyzes the reductive methylation of dUMP to form dTMP, which is the sole de novo source of thymidylate and is therefore essential for cell proliferation. TYMS is inhibited by 5-fluorouracil, an anticancer drug, which partly exerts its toxic activity by depleting the dTTP pool, thus leading to a thymine-less death. Patients with high tumor levels of TYMS are unlikely to respond to infusions of 5-fluorouracil, whereas patients with low levels show better response rates. 1 Genetic control of TYMS protein expression has been partially elucidated in recent years, and the essential role of the TYMS gene upstream region has been demonstrated. The TYMS-gene 5 0 untranslated region (5 0 UTR) contains tandemrepeated elements of a 28-bp sequence. The number of these repeats is variable (VNTR) and alleles with two (TYMS 2R) and three (TYMS 3R) repeats are the most common in all populations studied to date. The number of tandem repeats controls TYMS activity by affecting translational efficiency: TYMS mRNA with a three-repeat sequence has greater translational efficiency than that with a two-repeat sequence. 2 Mandola et al. 3 identified another common G-C SNP at the 12th nucleotide in the second repeat of the TYMS 3R allele. This base transversion changes a critical residue in the USF E-box consensus element, abolishes USF-1 binding and alters transcriptional activity. The same authors also used site-directed mutagenesis to produce 3R and 2R constructs containing altered E-box elements in all 28-bp repeats. Both constructs showed dramatically decreased transcriptional activity when compared with their wild-type counterparts. Kawakami and Watanabe 4 analyzed 258 tumor samples from Japanese patients, confirmed that the G-C substitution in the second repeat of the TYMS 3R allele has lower transcriptional activity and identified a new variant of the TYMS 2R allele in which both repeats contained guanine as 12th nucleotide. Functional analysis showed that the new TYMS 2R variant had the same translational efficiency as that of the wild-type allele, so that the frequency of this variant was not determined in the study population.
In this paper, a new allele variant in tandem repeat G-C polymorphism is described. During analysis of TYMS tandem repeat-G/C polymorphisms in a sample of 100 Caucasian colorectal cancer patients in three cases we observed an unexpected band after electrophoresis of restriction fragment length polymorphism analysis (RFLP) assay products. DNA sequencing demonstrated the existence of a TYMS 2R allele type, carrying a G-C base change in both 28-bp repeats. The clinical profiles of patients carrying this genotype are also reported.
Results
The frequencies of VNTR TYMS alleles in the 100 patients genotyped were 0.45 for TYMS 2R and 0.55 for TYMS 3R. One patient carried one allele with four tandem repeats (TYMS 4R). The corresponding genotype frequencies were: 2R/2R ¼ 0.21, 2R/3R ¼ 0.47, 3R/3R ¼ 0.31 and 2R/4R ¼ 0.01. The allele distribution was in Hardy-Weinberg equilibrium and showed no significant differences between males and females (data not shown). Analysis of G-C polymorphisms revealed that 97 patients out of 100 carried known TYMS allele variants, that is, 2R, 3RC, 3RG and 4R. However, in three cases, an unexpected 113-bp band appeared, as shown in Figures 1 and 2 . Therefore, we sequenced the PCR products that gave the 113-bp band and, in the TYMS 2R allele, sequencing analysis revealed cytosine instead of guanine at the 12th nucleotide in both 28-bp repeats ( Figure  3 ). This SNP (called TYMS 2RC to distinguish it from the wild-type 2RG allele) disrupts the HaeIII restriction site on the first 28-bp repeat of the TYMS 2R allele and explains the appearance of a longer band of RLFP electrophoresis products. The G-C SNP allele frequency, including the novel SNP, was: 2RG ¼ 0.43, 2RC ¼ 0.015, 3RG ¼ 0.23, 3RC ¼ 0.315 and 4R ¼ 0.005. The overall G-C genotype distribution was in Hardy-Weinberg equilibrium.
All patients with the new TYMS 2RC mutant allele were heterozygotes: two carried genotype 2RC/3RC and one genotype 2RG/2RC. The patient with the 2RG/2RC genotype could not tolerate standard doses of fluorouracil. She suffered grade 2 mucositis and grade 3 neutropenia after the first chemotherapy cycle, so that the dose had to be reduced. Despite this, the subsequent chemotherapy cycles had to be delayed because of grade 1-2 neutropenia and severe fatigue. Two years after the end of chemotherapy, she is still alive but has developed a cerebral metastasis. Of the two patients with the 2RC/3RC genotype, one developed grade 3 diarrhea and mucositis, but could maintain the standard fluorouracil doses with the aid of antidiarrhea drugs. Ten months after the end of chemotherapy, he developed multiple liver metastasis. The other 2RC/3RC patient could maintain the initial fluorouracil dose but all the following cycles had to be delayed because of recurring grade 2 neutropenia. During a 10-month follow-up, no systemic lesions were detected. Formal comparisons for toxicity and response with the other genotypes was not carried out, in view of the small number of subjects with the novel mutation, and the high variability in toxicity grade and response occurring in patients with already known genotypes.
Discussion
To date, two studies 3, 4 have reported the existence of a G-C SNP in the second repeat of TYMS 3R alleles with reduced transcriptional activity, and one of them 4 also found a TYMS 2R variant in which both repeats contained guanine as 12th nucleotide. As the latter variant showed the same translational efficiency as that of the wild type, typing of 2R alleles for G-C SNP was not performed in this study and in three subsequent genotyping studies. [5] [6] [7] To the best of our knowledge, ours is the first report in a human population of a TYMS 2R allele variant with both 28-bp tandem repeats bearing a cytosine at the 12th nucleotide. Apart from the three cases bearing a TYMS 2RC allele, the frequency of the other VNTR-G-C alleles in our series was similar to that previously reported for Caucasians. 3, 5 The reason for the relatively high frequency in our population (1.5%) of a previously unidentified polymorphism is unclear. One reason may be that in most previous studies the G-C SNP was not systematically analyzed, because it was believed that all 2R allele variants have similar translational activity.
Although a functional study of the TYMS 2RC variant has not been carried out, according to the site-directed mutagenesis experiments by Mandola et al., 3 in which the USF Ebox consensus element within the first TYMS 2R repeat was altered, the TYMS 2RC allele variant should express the lowest levels of TYMS activity, both in control conditions and under USF-1 stimulation. Accordingly, patients carrying this variant should be the most sensitive to the toxic effects of fluoropyrimidines. The clinical data available for our patients are too limited to allow any firm conclusion to be made in this regard. Also, no inference can be made about antitumor activity. Nevertheless, the existence of a new TYMS variant enlarges the range of possible TYMS transcriptional levels in cancer patients, and deserves further studies to assess its real clinical meaning.
Materials and methods

Patient population
Peripheral blood samples were obtained from 100 consecutive Caucasian patients (64 males, 36 females) with primary colorectal cancer, aged between 44 and 84 years (mean7 s.d. ¼ 64.279.3 years). Thirty-seven were in Dukes' stage B2 and 63 in stage C and underwent complete surgical resection, followed by adjuvant chemotherapy with intravenous (i.v.) 5-fluorouracil bolus plus folinic acid, according to the Mayo clinic protocol. 8 Toxicity grade was scored according to the criteria of the World Health Organization, 9 considering grade 0 'none', grade 1 'mild', grade 2 'moderate', grade 3 'severe' and grade 4 'life-threatening'. The project was approved by the local ethics committee and patients gave their consent to the genetic analysis.
Genetic analysis
White-cell genomic DNA was extracted from peripheral blood samples. For analysis of tandem repeat polymorphisms, PCR was used as described previously. 10 All samples were further analyzed for G-C polymorphisms by RFLP using HaeIII digestion as reported previously. 3 After electrophoresis on 3.5% gel (Agarose-1000, Invitrogen, Paisley, Scotland, UK), the G-C polymorphisms at the 12th nucleotide was identified as follows: the TYMS 3R allele carrying guanine in the first and second repeats (wild type ¼ 3RG) produced 66-, 47/44-, 28-and 12-bp bands; the TYMS 3R allele carrying guanine only in the first repeat produced 94-, 47/44-, 12-bp bands (mutant ¼ 3RC ); and the TYMS 2R allele carrying guanine in the first repeat (wild type ¼ 2RG) produced 66-, 47/44-and 12-bp bands. To test the reproducibility of the results 18 out of 100 samples were analyzed in duplicate and in all cases the results were confirmed. When a new band pattern appeared, PCR products were automatically sequenced (CEQ 2000XL DNA analyser, Beckman Coulter).
All allele distributions were examined for deviations from their corresponding Hardy-Weinberg equilibrium.
